HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.6%

Neg 0% Neu 86.6% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.